Hikma Pharmaceuticals USA has announced plans to invest $1bn by 2030 to enhance its manufacturing and research capabilities in the US.
This initiative aims to expand the company’s capacity to develop and produce a diverse array of generic medicines essential for the US healthcare system.
Since beginning its operations in the US in 1991, Hikma is said to have invested over $4bn in enhancing its domestic research and manufacturing infrastructure. These efforts have enabled the company to produce over 12 billion doses of essential medicines annually.
Hikma said that it has also collaborated with the US Food and Drug Administration (FDA) in addressing drug shortages.
The new investment will focus on increasing production across Hikma’s facilities located in Columbus and Cleveland, Ohio, as well as Cherry Hill and Dayton, New Jersey.
This expansion seeks to strengthen Hikma’s portfolio, which already includes more than 800 medicines. It will also boost its capability to supply large volumes of affordable, high-quality medicines to hospitals and healthcare providers across the US.
Hikma Rx president Hafrun Fridriksdottir said: “We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients.
“Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.”
Recently, Hikma launched Methylene Blue Injection, USP at a dosage of 50mg/10mL in the US. This product is intended for treating both paediatric and adult patients with acquired methemoglobinemia.
